Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ticagrelor vs Aspirin on Blood Viscosity in PAD with T2D
NCT02325466Phase 3Completed
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Apr 2015
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ticagrelor in peripheral artery disease (PAD) (3 arms), sponsored by Icahn School of Medicine at Mount Sinai. Primary endpoints: Mean Change in Low Shear Blood Viscosity at 16 weeks and Mean Change in High Shear Blood Viscosity at 16 weeks. Started Apr 2015; status: completed.
02
Drugs
ticagrelor
03
Conditions
peripheral artery disease (PAD)
Beyond the preview
Go deeper on NCT02325466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02325466.